It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pediatric liver tumors are very rare tumors with the most common diagnosis being hepatoblastoma. While hepatoblastomas are predominantly sporadic, around 15% of cases develop as part of predisposition syndromes such as Beckwith-Wiedemann (11p15.5 locus altered). Here, we identify mosaic genetic alterations of 11p15.5 locus in the liver of hepatoblastoma patients without a clinical diagnosis of Beckwith-Wiedemann syndrome. We do not retrieve these alterations in children with other types of pediatric liver tumors. We show that mosaic 11p15.5 alterations in liver FFPE sections of hepatoblastoma patients display IGF2 overexpression and H19 downregulation together with an alteration of the liver zonation. Moreover, mosaic livers’ microenvironment is enriched in extracellular matrix and angiogenesis. Spatial transcriptomics and single-nucleus RNAseq analyses identify a 60-gene signature in 11p15.5 altered hepatocytes. These data provide insights for 11p15.5 mosaicism detection and its functional consequences during the early steps of carcinogenesis.
Paediatric liver cancer is rare, and often associated with a predisposition syndrome. Here, the authors show that 11p15.5 mosaic alteration in the liver is a pre-neoplastic lesion associated with hepatoblastoma, and spatial transcriptomics together with single-nucleus RNAseq identify a an altered zonation in the liver of these patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Paris, France (GRID:grid.417925.c)
2 Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
3 CHU Rennes, Department of Paediatrics, Rennes, France (GRID:grid.411154.4) (ISNI:0000 0001 2175 0984)
4 Paris-Saclay University, Department of Pediatric Surgery, Bicêtre Hospital, AP-HP, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
5 Université Paris Cité, Department of Pediatric Surgery, Hôpital Necker-Enfants Malades, AP-HP, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
6 Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384)
7 Pathology Department, Necker Enfants Malades Hospital, Université Paris Cité, AP-HP, Paris, France (GRID:grid.412134.1) (ISNI:0000 0004 0593 9113)
8 Paris-Saclay University, Department of Pathology Hôpital Bicêtre–AP-HP, INSERM U1193, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
9 Centre de Recherche des Cordeliers, Université Paris Cité, Sorbonne Université, Inserm, Paris, France (GRID:grid.417925.c); Department of Oncology, Hopital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP, Paris, France (GRID:grid.414093.b) (ISNI:0000 0001 2183 5849)